Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class

N Engl J Med. 2019 Jul 4;381(1):1-4. doi: 10.1056/NEJMp1903305. Epub 2019 May 22.

Authors

Jean Kim¹, Tiffany Farchione¹, Andrew Potter¹, Qi Chen¹, Robert Temple¹

Affiliation

¹ From the Food and Drug Administration, Silver Spring, MD.

PMID: 31116916
DOI: 10.1056/NEJMp1903305

No abstract available

MeSH terms

Antidepressive Agents / adverse effects
Antidepressive Agents / therapeutic use*
Drug Approval*
Humans
Ketamine / adverse effects
Ketamine / therapeutic use*
United States
United States Food and Drug Administration

Substances

Antidepressive Agents
Esketamine
Ketamine